🔎 Trials Near Me

Akèy › Maladi poumon entèstisyèl › Ohio › Cleveland

Etid klinik pou Maladi poumon entèstisyèl nan Cleveland, OH

5 etid pou Maladi poumon entèstisyèl ap chèche patisipan nan sit nan ak bò kote Cleveland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

Ap rekriteFaz 3
  • University Hospitals Cleveland Medical Center, Cleveland
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07540988

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Ap rekrite
  • University Hospitals Cleveland Medical Center, Cleveland
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06911632

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Ap rekriteEtid obsèvasyon
  • University Hospitals Cleveland Medical Center, Cleveland
  • The Cleveland Clinic, Cleveland
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06388421

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Ap rekriteEtid obsèvasyon
  • Cleveland Clinic, Cleveland
Laj 21 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT01915511

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Ap rekriteFaz 2
  • aTyr Investigative Site, Cleveland
Laj 18 ak plis · Tout sèks · Mizajou May 7, 2025 · NCT05892614

Etid Maladi poumon entèstisyèl nan lòt vil

Lòt etid nan Cleveland

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.